Search Results - "Rana, M.A.H."

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression by Andersen, R., Borch, T.H., Draghi, A., Gokuldass, A., Rana, M.A.H., Pedersen, M., Nielsen, M., Kongsted, P., Kjeldsen, J.W., Westergaard, M.C.W., Radic, H.D., Chamberlain, C.A., Hölmich, L.R., Hendel, H.W., Larsen, M.S., Met, Ö, Svane, I.M., Donia, M.

“…Almost half of the patients with metastatic melanoma obtain only short-term or no benefit at all from checkpoint inhibitor (CPI) immunotherapy. In this study,…”
Get full text

T-cell therapy in combination with vemurafenib in BRAF mutated metastatic melanoma patients by Borch, T.H., Andersen, R., Rana, M.A.H., Kongsted, P., Pedersen, M., Nielsen, M., Kjeldsen, J.W., Kverneland, A., Met, Ö, Donia, M., Svane, I.M.

Get full text

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor induction in checkpoint inhibitor resistant metastatic melanoma patients by Borch, T.H., Andersen, R., Rana, M.A.H., Kongsted, P., Pedersen, M., Nielsen, M., Kjeldsen, J.W., Kverneland, A., Lorentzen, C.L., Met, Ö, Donia, M., Svane, I.M.

Get full text

T cell responses in patients with melanoma resistant to multiple immunotherapies by Andersen, R., Borch, T.H., Draghi, A., Gokuldass, A., Rana, M.A.H., Pedersen, M., Nielsen, M., Kongsted, P., Kjeldsen, J.W., Westergaard, M.C.W., Hölmich, L.R., Hendel, H.W., Larsen, M.S., Met, Ö, Svane, I.M., Donia, M.

Get full text